VYNE Therapeutics (US:VYNE)2025-11-06 13:02Financial Position - As of September 30, 2025, VYNE had cash, cash equivalents, and marketable securities totaling $32.7 million, sufficient to fund operations into the first half of 2027[10] - The total stockholders' equity as of September 30, 2025, was $32.1 million, down from $52.1 million at the end of 2024[21] Revenue Performance - Revenues for the third quarter of 2025 were $0.2 million, compared to $0.1 million for the same period in 2024, primarily from royalty revenue[11] - Total revenues for the three months ended September 30, 2025, were $169 million, an increase from $121 million in the same period of 2024, representing a growth of 39.7%[23] - Royalty revenues for the nine months ended September 30, 2025, reached $440 million, compared to $417 million in 2024, indicating a year-over-year increase of 5.5%[23] Expenses and Losses - Research and development expenses decreased by $5.0 million, or 48.7%, to $5.3 million for the third quarter of 2025, down from $10.2 million in the same quarter of 2024[12] - VYNE's general and administrative expenses for the third quarter of 2025 were $2.7 million, a decrease of approximately $0.3 million, or 8.7%, compared to $3.0 million in the same quarter of 2024[14] - Total operating expenses for the three months ended September 30, 2025, were $7,961 million, down from $13,212 million in the same period of 2024, reflecting a decrease of 39.5%[23] - The operating loss for the three months ended September 30, 2025, was $(7,792) million, an improvement from $(13,091) million in the same period of 2024[23] - Net loss for the three months ended September 30, 2025, was $(7,280) million, compared to $(12,157) million in the same period of 2024, showing a reduction of 40.5%[23] - Loss per share from continuing operations for the three months ended September 30, 2025, was $(0.17), an improvement from $(0.29) in the same period of 2024[23] - Research and development expenses for the nine months ended September 30, 2025, totaled $16,260 million, down from $21,262 million in 2024, a decrease of 23.5%[23] - General and administrative expenses for the nine months ended September 30, 2025, were $8,710 million, compared to $10,022 million in 2024, reflecting a decrease of 13.1%[23] - Other income for the three months ended September 30, 2025, was $366 million, compared to $934 million in the same period of 2024[23] Clinical and Strategic Developments - VYNE is conducting a 12-week non-clinical toxicology study of VYN202 in dogs to address a partial hold on clinical trials for male subjects[3] - The strategic review initiated by VYNE's Board of Directors includes evaluating internal pipeline opportunities and potential strategic partnerships or acquisitions[4] - The Phase 1b trial of VYN202 in moderate-to-severe plaque psoriasis was placed on clinical hold by the FDA due to testicular toxicity observations, but the hold was lifted for female subjects[8] - VYNE is seeking a development and commercialization partner for the repibresib gel program, which is covered by patents providing exclusivity into at least 2042 in the U.S.[13] Share Information - Weighted average shares outstanding for the three months ended September 30, 2025, were 42,801 million, slightly up from 42,587 million in the same period of 2024[23]